project id: TCGA-BLCA; case submitter id: TCGA-G2-A2EF; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.7; rna integrity number: 7.7; age at index: 50; days to birth: -18467; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1957; age at diagnosis: 18467; ajcc clinical t: T2a; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1884.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2007; alcohol history: Not Reported; cigarettes per day: 1.917808219178082; pack years smoked: 35.0; is ffpe: false; composition: Not Reported; days to collection: 1485; days to sample procurement: 0; initial weight: 120.0; portion submitter id: TCGA-G2-A2EF-01A-12; percent lymphocyte infiltration: 4.0; percent monocyte infiltration: 3.0; percent necrosis: 15.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 60.0; percent tumor nuclei: 75.0;